A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets
{{output}}
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality worldwide; however, precision oncology has fundamentally transformed its treatment landscape. In 2025, seven approvals by the U.S. Food and Drug Administration (FDA) further accel... ...
